Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/AARTIDRUGS stock hub

NSE/AARTIDRUGS has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/AARTIDRUGSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

35.5B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/AARTIDRUGS

In the news

Latest news · NSE/AARTIDRUGS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E17.4

P25 24.9P50 32.4P75 45.7

Trailing P/E17.5

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC11.5

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/AARTIDRUGS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

199

Groups with data

Currency

INR

Showing 199 of 199 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	1,284
Employees Change	220%
Employees Change Percent	20.68
Enterprise value	INR 40.9B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE767A01016
Last refreshed	2026-05-10
Market cap	INR 35.5B
Price	INR 387
Price currency	INR
Rev Per Employee	19,639,955.61x
Sector	Healthcare
Sic	2836
Symbol	nse/AARTIDRUGS
Website	https://www.aartidrugs.co.in

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.71%
EV Earnings	20.21x
EV/EBIT	16.86x
EV/EBITDA	13.64x
EV/Sales	1.62x
Forward P/E	17.4x
P/B ratio	2.41x
P/E ratio	17.5x
P/S ratio	1.41x
PE Ratio10 Y	20.13x
PE Ratio3 Y	24.07x
PE Ratio5 Y	23.91x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	9.63%
EBITDA Margin	11.86%
Gross margin	35.46%
Gross Profit	INR 8.9B
Gross Profit Growth	10.57%
Gross Profit Growth Q	4.8%
Gross Profit Growth3 Y	3.61%
Gross Profit Growth5 Y	2.01%
Net Income	INR 2B
Net Income Growth	32.74%
Net Income Growth Q	9.42%
Net Income Growth Quarters	5%
Net Income Growth Years	0%
Net Income Growth3 Y	6.96%
Net Income Growth5 Y	-6.77%
Pretax Margin	8.39%
Profit Margin	8.03%
Profit Per Employee	INR 1.6M
Profitable Years	20
Roa5y	8.62
Roe5y	19.66
ROIC	11.51
Roic5y	14.71

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	13.08%
Cagr15y	24.57%
Cagr1y	-7.45%
Cagr20y	21.74%
Cagr3y	-4.34%
Cagr5y	-12.9%
Div CAGR10	23.11%
Div CAGR3	25.99%
Div CAGR5	14.87%
EPS Growth	32.91
EPS Growth Q	9.38
EPS Growth Quarters	5
EPS Growth Years	0
EPS Growth3 Y	7.46
EPS Growth5 Y	-6.39
Revenue Growth	8.22x
Revenue Growth Q	8.11x
Revenue Growth Quarters	4x
Revenue Growth Years	0x
Revenue Growth3 Y	-1.86x
Revenue Growth5 Y	3.7x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 245.4M
Debt	INR 5.7B
Debt EBITDA	INR 1.91
Debt Equity	INR 0.39
Equity	INR 14.7B
Interest Coverage	7
Net Cash	INR -5.5B
Net Cash By Market Cap	INR -15.48
Net Debt EBITDA	INR 1.84
Net Debt Equity	INR 0.37
Tangible Book Value	INR 14.6B
Tangible Book Value Per Share	INR 148
WACC	6.18

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.18%
Dividend Growth	100%
Dividend Growth Years	0%
Dividend per share	INR 2
Dividend Years	5
Dividend Yield	0.5%
Ex Div Date	2026-02-09
Last Dividend	INR 2
Payout Frequency	Annual

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	241.85%
1Y total return	-7.45%
200-day SMA	430.8
3Y total return	-12.45%
50-day SMA	360.5
50-day SMA vs 200-day SMA	50under200
5Y total return	-49.86%
All Time High	1,027
All Time High Change	-62.36%
All Time High Date	2020-10-08
All Time Low	3.95
All Time Low Change	9,684.81%
All Time Low Date	2009-02-20
ATR	12.7
Beta	0.36
Ch YTD	-6.11
High	399.9
High52	564.1
High52 Date	2025-07-21
High52ch	-31.48%
Low	385.1
Low52	319
Low52 Date	2026-03-30
Low52ch	21.18%
Ma50ch	7.21%
Price vs 200-day SMA	-10.28%
RSI	58.27
RSI Monthly	45.38
RSI Weekly	49.12
Sharpe ratio	0.37x
Sortino ratio	0.81
Total Return	0.68%
Tr YTD	-5.61
Tr15y	2,600%
Tr1m	8.29%
Tr1w	-2.36%
Tr3m	3.72%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 2.4B
Operating Income Growth	2.68
Operating Income Growth Q	-38.01
Operating Income Growth3 Y	-0.91
Operating Income Growth5 Y	-8.45
Operating margin	9.63

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	35,372,091%
Shares Insiders	47.31%
Shares Institutions	19.19%
Shares Qo Q	-7.68%
Shares Yo Y	-0.18%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	162,703.3x
Bv Per Share	148.5
Ch10y	232.9
Ch15y	2,098.4
Ch1m	8.29
Ch1w	-2.36
Ch1y	-7.94
Ch20y	3,395.8
Ch3m	3.16
Ch3y	-13.29
Ch5y	-50.56
Ch6m	-21.36
Change	-2.8%
Change From Open	-2.21
Close	397.7
Days Gap	-0.6
Depreciation Amortization	560,936,250
Dollar Volume	51,186,900.5
Earnings Date	2026-05-15
EBIT	INR 2.4B
EBITDA	INR 3B
EPS	INR 22.18
F Score	2
Fiscal Year End	March
Founded	1,984
Graham Number	282.04898
Graham Upside	-27.02
Income Tax	INR 92.5M
Is Primary Listing	0
Last Earnings Date	2026-01-23
Last Report Date	2025-12-31
Last Split Date	2020-09-30
Last Split Type	Forward
Lynch Fair Value	INR 110
Lynch Upside	-71.43
Ma150	407.1
Ma150ch	-5.06%
Ma20	374.5
Ma20ch	3.22%
Next Earnings Date	2026-05-15
Open	395.3
Payment Date	2026-03-05
Position In Range	9.46
Price Date	2026-05-08
Price EBITDA	INR 11.86
Ptbv Ratio	2.43
Relative Volume	0.81x
Revenue	25,217,703,000x
Tax By Revenue	0.37x
Tax Rate	4.37%
Tr20y	5,010.68%
Tr6m	-20.93%
Volume	132,437

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/AARTIDRUGS dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.5%

$2.00 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+14.9%

0 consecutive years of growth

Total shareholder yield

+0.7%

Next ex-dividend date: 2026-02-09

Performance

NSE/AARTIDRUGS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/AARTIDRUGS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+19.2%

Share of float held by funds and institutions

Insider ownership

+47.3%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.2%

Negative means the company is buying back shares.

Technical

NSE/AARTIDRUGS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

58.3

Neutral momentum band

Price vs 200-day MA

-10.3%

50/200-day relationship not available

Beta (5Y)

0.36

Less volatile than the market

Sharpe ratio

0.37

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/AARTIDRUGS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/AARTIDRUGS stock rating?

nse/AARTIDRUGS is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/AARTIDRUGS analysis?

The full report lives at /stocks/nse/AARTIDRUGS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/AARTIDRUGS?

The latest report frames nse/AARTIDRUGS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/AARTIDRUGS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.